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Background: Middle East respiratory syndrome coronavirus (MERS-CoV) continues to 
cause human infections with multiple clusters two years after the onset of the epidemic. 
Though mild cases have been recognized, the infection is severe in those with co-
morbidities and >30% of patients die from the infection. Our recent structure-based 
development of a fusion inhibitor is one of the few treatment options for MERS and it led 
us to hypothesize that other existing antivirals that block cellular entry may also be active 
against MERS-CoV.1 BanLec is a jacalin-related banana lectin that has potent anti-HIV 
activity through binding to glycosylated viral envelope proteins and blocking cellular entry. 
We assessed the anti-MER-CoV activity of BanLec in cell culture assays. 
 
Methods: The anti-MERS-CoV activity of BanLec was assessed by cytopathic effect 
inhibition, viral yield reduction, and plaque reduction assays in Vero, Calu-3, and/or HK2 
cells as previously described.2 The cytotoxicity of BanLec was also assessed. 
 
Results: The CC50 of BanLec was >10 nM in Vero and Calu-3 cells. CPE was completely 
absent in Vero and HK2 cells infected with MERS-CoV on 3 dpi with 30.00 nM of BanLec. In 
Calu-3 cells, CPE was completely absent at 90.00 nM of the drug. The EC50 of BanLec 
ranged from 3.99-4.82 nM (Table 1). 
 
Conclusion: BanLec exhibits potent in vitro anti-MERS-CoV activity. The detailed 
mechanism and in vivo correlation of its antiviral activity should be further tested in 
animal models. The potential advantages of using BanLec for MERS include its high 
stability and the prospect of using it as a topical treatment or prophylaxis for exposed 
patients. 
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Table 1. Inhibitory effect of BanLec on MERS-CoV (cytopathic effect inhibition) 
Fig. 1. Inhibitory effect of BanLec on MERS-CoV (viral yield reduction) 
Vero: ↓ 7.13 log10 copies/ml 
HK2: ↓ 3.40 log10 copies/ml Calu-3: ↓ 3.63 log10 copies/ml 
Fig. 2. Inhibitory effect of BanLec on MERS-CoV (plaque reduction assay) 
Vero: 100% reduction (>10nM) HK2: 59.5% reduction (>10nM) 
aEC50 was determined by CPE inhibition assay in Vero and Calu-3 cells, and by PRA in the HK2 cells 
bNA, not available; cSelectivity index = CC50/EC50. 
